TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06436820

Intervention type: PROCEDURE
Intervention: Lumbar puncture
Description: Lumbar puncture procedure performed within a clinical setting
Study: NCT06316648

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: whey intake group
Description: It was prepared at the bedside by the first investigator for the patients in the oral whey intervention group by mixing 54 grams of 70% demineralized whey powder taken from the herbalist into 600 ml of drinking water six hours before the surgery, and the patients were given 400 ml six hours before the surgery and 200 ml two hours before the surgery. They were given ml and allowed to drink.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: control group
Description: The patients were left fasting after 00:00.
Study: NCT04694716

Intervention type: OTHER
Intervention: No intervention
Description: No intervention will be applied.

Intervention type: OTHER
Intervention: No intervention
Description: No intervention will be applied.
Study: NCT04859543

Intervention type: DEVICE
Group type: OTHER
Intervention: FoundationOneHeme
Description: Tumor tissue obtained during standard surgery will be subsequently examined histopathologically and the content of cancer cells will be determined. Broad molecular profiling of the tumor; with potential results finding such molecular changes, for which the specific targeted anti-tumor treatment will be performed.
Study: NCT05988632

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Regular Human Insulin then Placebo
Description: Insulin: 80 IU (administered intranasally) THEN Placebo: 0.9% saline solution (administered intranasally)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo then Regular Human Insulin
Description: Placebo: 0.9% saline solution (administered intranasally) THEN Insulin: 80 IU (administered intranasally)
Study: NCT04571151

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: LEXETTE 0.05% Topical Foam
Description: Halobetasol Propionate Topical Foam (Lexette Foam) would be applied over the affected area twice daily for 2 weeks.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: LEXETTE 0.05% Topical Foam
Description: Halobetasol Propionate Topical Foam (Lexette Foam) would be applied over the affected area twice daily for 2 weeks.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sorilux 0.005 % Topical Foam
Description: Calcipotriol Foam (Sorilux Foam) would be applied over the affected area twice daily for 2 weeks 5 minutes after the Lexette application. SORILUX Foam contains calcipotriene 50 mcg/g.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sorilux 0.005 % Topical Foam
Description: Calcipotriol Foam (Sorilux Foam) would be applied over the affected area twice daily for 2 weeks 5 minutes after the Lexette application. SORILUX Foam contains calcipotriene 50 mcg/g.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Vehicle Foam
Description: Vehicle Foam would be applied over the affected area twice daily for 6 weeks.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Vehicle Foam
Description: Vehicle Foam would be applied over the affected area twice daily for 6 weeks.
Study: NCT04746677

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Endovascular aortic repair with a physician-modified endovascular graft (PMEG)
Description: Endovascular aortic repair with a physician-modified endovascular graft (PMEG)
Study: NCT05750862

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Marking of the intended axis of IOL-Implantation manually with an ink and marking device on the surface of the eye
Description: The marking of the intended implantation axis of the interocular lens will be marked in all patients with topography guided in the corneal stroma with laser and in addition manually with a caliper and ink on the corneal surface
Study: NCT05191017

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NUV-422
Description: NUV-422 is an investigational drug for oral dosing.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NUV-422
Description: NUV-422 is an investigational drug for oral dosing.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Enzalutamide
Description: Enzalutamide

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Enzalutamide
Description: Enzalutamide
Study: NCT04819048

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Low-Level Laser Therapy+acupuncture
Description: The experimental group will be firstly irradiated by the GaAlAs infrared laser (CDHC,Denlase 980/7 Diode Laser Therapy System,China), with an output of 500 mW, emitting radiation wavelength of 980 nm, spot size 0.2cm2 ,15J/point, in a continuous mode .The therapeutic LLLT application is achieved through direct contact of the probe on the skin.~The needles using are disposable, sterile, individually packed, and made of stainless steel (Hua Tuo; Suzhou Medical Supplies Factory Co, Ltd,Suzhou, China), in sizes 0.25 mm ×40 mm.Asepsis of the skin will be performed with cotton wool and 75% alcohol.
Study: NCT04819048

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Low-Level Laser Therapy
Description: The experimental group will be firstly irradiated by the GaAlAs infrared laser (CDHC,Denlase 980/7 Diode Laser Therapy System,China), with an output of 500 mW, emitting radiation wavelength of 980 nm, spot size 0.2cm2 ,15J/point, in a continuous mode .The therapeutic LLLT application is achieved through direct contact of the probe on the skin.
Study: NCT05084716

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Enhanced PrEP provision
Description: At the intervention site during healthcare facility outreach events, all community members will be offered the opportunity to attend intervention workshops where they can learn basic facts about PrEP and be taught skills about how to advocate for PrEP in their community. Check-in reminder calls will be conducted systematically with PrEP users. Healthcare facility staff will encourage PrEP initiators to select an adherence supporter.
Study: NCT06388759

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TQ05105 Tablets
Description: TQ05105 Tablets is a Janus kinase 1 (JAK1) and Janus kinase 2 （JAK2） Inhibitor
Study: NCT06312657

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Drug Cue
Description: Individualized drug cues paired with choice options reinforced by $0.25

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Money
Description: Two money values will be tested ($0.25 and $4.00)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Withdrawal
Description: Participants will be maintained on an opioid agonist. Placebo will be substituted to produce mild-to-moderate withdrawal.
Study: NCT06330181

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: VR Game 1
Description: Individuals playing VR game 1 will wear a head-mounted display to allow them to visualize virtual legs in the virtual environment. When wearing the display, individuals will see the legs and arms of their virtual avatar from a first-person perspective.~Individuals will engage in virtual reality sessions in their home twice daily over the course of 10 days in a two-week period. Each daily session will take approximately 30 minutes, with 5-10 minutes dedicated to the virtual walking experience. Additionally, each daily session will be scheduled a minimum of 4 hours apart

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: VR Game 2
Description: Individuals playing VR game 2 will wear a head-mounted display to allow them to visualize virtual legs in the virtual environment. When wearing the display, individuals will see the legs and arms of their virtual avatar from a first-person perspective.~Individuals will engage in virtual reality sessions in their home twice daily over the course of 10 days in a two-week period. Each daily session will take approximately 30 minutes, with 5-10 minutes dedicated to the virtual walking experience. Additionally, each daily session will be scheduled a minimum of 4 hours apart.
Study: NCT04746677

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Endovascular aortic repair with a physician-modified endovascular graft (PMEG)
Description: Endovascular aortic repair with a physician-modified endovascular graft (PMEG)

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Endovascular aortic repair with a physician-modified endovascular graft (PMEG)
Description: Endovascular aortic repair with a physician-modified endovascular graft (PMEG)
Study: NCT05653856

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 64Cu-PSMA I&T
Description: Radiolabeled Receptor-Targeted Diagnostic Product
Study: NCT05727371

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Regen Matrix-PRP-XLHA
Description: Single intra-articular injection at Day 0

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Hylan G-F 20
Description: Single intra-articular injection at Day 0

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Single intra-articular injection at Day 0
Study: NCT05632211

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: AVT05
Description: Pre filled syringes filled with AVT05

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Simponi
Description: Pre filled syringes filled with Simponi

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Simponi
Description: Pre filled syringes filled with Simponi
Study: NCT05556759

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: control
Description: patient will be operated under general anesthesia

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: IPS
Description: patients will receive ultrasound-guided anterior IPS block with 30 ml of bupivacaine 0.25% followed by general anesthesia.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Supra-iliac QL
Description: patients will receive ultrasound-guided supra-iliac anterior QL block with 30 ml of bupivacaine 0.25% followed by general anesthesia.
Study: NCT04664790

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Hyperbaric Oxygen
Description: Each session will include exposure of 90 minutes to 100% at 2 ATA, with 5 minutes air breaks every 20 minutes

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Cognitive training
Description: Neuropsychologist guided BrainHQ training
Study: NCT06573528

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CS060380
Description: Tablets administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CS060380
Description: Tablets administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CS060380
Description: Tablets administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CS060380
Description: Tablets administered orally
Study: NCT05043844

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: abdominal binder
Description: Wearing an abdominal binder postoperatively
Study: NCT04695145

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Aerobic exercise in group
Description: Progression~The goal with every new week should be making every workout a little bit harder than the week before.~Strength sessions~* Week 1-6: 12-18 reps x 2 set per exercise and muscle 30 s rest between exercises~* Week 7-12: 10-12 reps x 3 set per exercise and muscle 20 s rest between exercises~Adding weight with gym equipment or changing body position in the exercises to succeed with the rep scheme and making it harder as the group develop their physical and mental ability.~Conditioning sessions~* Week 1-6: 75 seconds work time x 1 set per exercise 30 seconds of rest between exercises~* Week 7-12: 50 seconds work time x 2 set per exercise 20 seconds of rest between exercises~Mixed sessions~* Week 1-6: 35 s work time per exercise 25 s rest between exercises x 2 rounds~* Week 7-12: 45 s work time per exercise 15 s rest between exercises x 2 rounds

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Group sessions with leisure activities
Description: The control group will receive leisure activity in a group setting for one hour three times a week for 12 weeks. The sessions will be held at the same weekdays and about the same hours as the exercise group sessions. The same group leaders as in the exercise sessions will participate in leisure sessions and will support the adolescents through reminders and reassurance before and during the sessions to enhance adherence. The sessions will start with a check in on feelings, recent events and difficulties (i.e. supportive listening but not any interventions) followed by non heart rate increasing activities, such as playing games or watching movies together.
Study: NCT05044390

Intervention type: PROCEDURE
Intervention: Lung transplantation (single, lobar or bilateral lung transplantation)
Description: Lung transplantation were performed for end-stage interstitial lung disease secondary to pleuroparenchymal fibroelastosis
Study: NCT05968391

Intervention type: RADIATION
Intervention: PET scan metabolic day
Description: 11C-Acetate and 11C-Acetoacetate PET scans
Study: NCT04669600

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SAR445088 (BIVV020)
Description: Pharmaceutical form:solution for injection
Study: NCT05338593

Intervention type: OTHER
Intervention: Outcome
Description: Mortality rate of prolonged therapy.
Study: NCT05504564

Intervention type: GENETIC
Intervention: The experiment does not required any intervention
Description: The experiment does not required any intervention
Study: NCT06573528

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CS060380
Description: Tablets administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CS060380
Description: Tablets administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CS060380
Description: Tablets administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CS060380
Description: Tablets administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CS060380
Description: Tablets administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CS060380
Description: Tablets administered orally
Study: NCT04544189

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alpelisib
Description: 300mg (oral) once daily, in a 28-day cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alpelisib
Description: 300mg (oral) once daily, in a 28-day cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fulvestrant
Description: Fulvestrant 500 mg (intramuscular, as two 250mg/5 mL injections) on Day 1 and 15 of Cycle 1 and on Day 1 of every Cycle thereafter

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fulvestrant
Description: Fulvestrant 500 mg (intramuscular, as two 250mg/5 mL injections) on Day 1 and 15 of Cycle 1 and on Day 1 of every Cycle thereafter

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Fulvestrant
Description: Fulvestrant 500 mg (intramuscular, as two 250mg/5 mL injections) on Day 1 and 15 of Cycle 1 and on Day 1 of every Cycle thereafter

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 300 mg by mouth once daily, in a 28-day cycle
Study: NCT05734833

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Culturelle Probiotic + Fiber
Description: The experimental group will receive the study product which is Culturelle Probiotic + Fiber

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The Placebo comparator arm will receive placebo sachets
Study: NCT06494111

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pravastatin
Description: Given by PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pentoxifylline
Description: Given by PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tocopherol
Description: Given by PO
Study: NCT04723303

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Umbilical Cord Lining Stem Cells
Description: An IV infusion of ULSCs will be administered.
Study: NCT06633419

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Opevesostat
Description: Administered via oral tablet per dosing regimen.
Study: NCT04814511

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: InfectoScab 5 % Creme
Description: InfectoScab 5 % Creme is the already approved standard therapeutic agent, containing the active ingredient permethrin in 5 % concentration. In this study, it is used for topical treatment in the first treatment cycle (standard therapy) as well as in the second treatment cycle (escalation therapy).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: InfectoScab 5 % Creme
Description: InfectoScab 5 % Creme is the already approved standard therapeutic agent, containing the active ingredient permethrin in 5 % concentration. In this study, it is used for topical treatment in the first treatment cycle (standard therapy) as well as in the second treatment cycle (escalation therapy).

Intervention type: DRUG
Group type: OTHER
Intervention: InfectoScab 5 % Creme
Description: InfectoScab 5 % Creme is the already approved standard therapeutic agent, containing the active ingredient permethrin in 5 % concentration. In this study, it is used for topical treatment in the first treatment cycle (standard therapy) as well as in the second treatment cycle (escalation therapy).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Permethrin 10 % Creme
Description: Permethrin 10 % Creme also contains permethrin as the active ingredient, but in 10 % concentration. Permethrin 10 % creme is used exclusively for topical treatment in the second therapy cycle (escalation therapy).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Driponin 3 mg Tabletten
Description: Driponin 3 mg Tabletten are approved for the treatment of scabies, containing ivermectin as the active ingredient. Driponin is used as a supplementary, peroral add-on combination treatment in addition to topical permethrin therapy and is used exclusively in the second treatment cycle (escalation therapy).
Study: NCT05417659

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Exercise plus carbohydrate
Description: A high carbohydrate drink to be consumed 1 hour prior to exercise and every 15 minutes during exercise.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Exercise plus niacin
Description: A dose of niacin to be consumed 30 minutes prior to exercise, at onset of exercise and 30 minutes into exercise.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: A placebo drink to be consumed 1 hour prior to exercise and every 15 minutes during exercise and placebo tablets to be consumed 30 minutes prior to exercise, at the onset of exercise and 30 minutes into exercise.
Study: NCT06118554

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Irrigation head position
Description: Patients irrigated their sinuses with once daily 2 mg mometasone using 240 mL NeilMed sinus rinse bottles for 8 weeks. The only factor that varied between groups was the head position patients irrigated in.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Irrigation head position
Description: Patients irrigated their sinuses with once daily 2 mg mometasone using 240 mL NeilMed sinus rinse bottles for 8 weeks. The only factor that varied between groups was the head position patients irrigated in.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Irrigation head position
Description: Patients irrigated their sinuses with once daily 2 mg mometasone using 240 mL NeilMed sinus rinse bottles for 8 weeks. The only factor that varied between groups was the head position patients irrigated in.
Study: NCT06512831

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Isoniazid
Description: Those with risk factors were recommended a 6-month prophylaxis regimen, consisting of INH (300 mg/d) and pyridoxine (10 mg/d to prevent INH-related neurotoxicity).
Study: NCT05944913

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Prevena
Description: PREVENA™ is a CE-marked class IIa medical device. The PREVENA™ Incision Management System is also intended to manage the environment of closed surgical incisions and surround intact skin in patients at risk for developing post-operative complications, such as infection, by maintaining a closed environment via the application of a negative pressure wound therapy system to the incision.
Study: NCT05228756

Intervention type: OTHER
Group type: OTHER
Intervention: Accelerometer
Description: Participants will complete 16 exercise sessions at home wearing an accelerometer
Study: NCT06058884

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Alteplase
Description: Following the guidelines set forth by the American Heart Association/American Stroke Association (AHA/ASA), inclusion and exclusion criteria for alteplase were established; 0.9 mg/kg of alteplase up to a maximum dose of 90 mg was administered intravenously to eligible individuals within 4.5 hours of the beginning of their clinical manifestations (10% bolus, 90% infusion in 1 hour). After receiving IV-alteplase, all patients continued their management and rehabilitation in the stroke unit.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Alteplase
Description: Following the guidelines set forth by the American Heart Association/American Stroke Association (AHA/ASA), inclusion and exclusion criteria for alteplase were established; 0.9 mg/kg of alteplase up to a maximum dose of 90 mg was administered intravenously to eligible individuals within 4.5 hours of the beginning of their clinical manifestations (10% bolus, 90% infusion in 1 hour). After receiving IV-alteplase, all patients continued their management and rehabilitation in the stroke unit.
Study: NCT05337345

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cendakimab
Description: Specified Dose on Specified Days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cendakimab
Description: Specified Dose on Specified Days
Study: NCT04841213

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Dental implantation
Description: Traditional 2-stage dental implantation according to surgical protocols of dental implant systems (Straumann (Institut Straumann AG, Switzerland), Astra Tech (Dentsply Implant Manufacturing GmbH, Germany), Xive (FRIADENT GmbH, Germany), Alpha Bio (Alpha Bio Tec Ltd., Israel) for different types of bone tissue

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Dental implantation
Description: Traditional 2-stage dental implantation according to surgical protocols of dental implant systems (Straumann (Institut Straumann AG, Switzerland), Astra Tech (Dentsply Implant Manufacturing GmbH, Germany), Xive (FRIADENT GmbH, Germany), Alpha Bio (Alpha Bio Tec Ltd., Israel) for different types of bone tissue
Study: NCT06268509

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Nutritional panel laboratory examination
Description: As stated in group description

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Pregnancy supplements (other than provided by Ministry of Health)
Description: As stated in group description

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Fetomaternal ultrasound
Description: As stated in group description